Questions About Cancer? 1-800-4-CANCER
NCI Cancer Center News

Personalized vaccine for most lethal type of brain tumor shows promise

  • Posted: December 17, 2013

Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro-Oncology and accompanied by an editorial highlighting the importance of the trial. This phase 2 trial, conducted by researchers from the Northwestern Feinberg School of Medicine and its Robert H. Lurie Comprehensive Cancer Center, enrolled 41 adult patients with recurrent tumors between 2007 and 2011.

Click here to read the full press release.

###

NCI Comprehensive Cancer Center logoAmong the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.